REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease

Trial Profile

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Anacetrapib (Primary)
  • Indications Cardiovascular disorders; Coronary disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms REVEAL
  • Most Recent Events

    • 27 Jun 2017 According to Merck & Co media release, this trial was conducted in collaboration with the TIMI Study Group based at Brigham and Womens Hospital in Boston.
    • 27 Jun 2017 According to Merck & Co media release, results of this trial will be presented at the European Society of Cardiology meeting on Aug. 29, 2017.
    • 27 Jun 2017 According to Merck & Co media release, the company is planning to review the results of the trial with external experts and will consider whether to file new drug applications with the U.S. Food and Drug Administration (FDA) and other regulatory agencies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top